SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

29 May 2025 Evaluate
The revenue zoomed 8.46% to Rs. 16384.40 millions for the quarter ended March 2025 as compared to Rs. 15106.40 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2025 is Rs. -650.50 millions as compared to Net Profit of Rs. 647.60 millions of corresponding quarter ended March 2024The company reported a good operating profit of 3800.80 millions compared to 3074.40 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 16384.40 15106.40 8.46 66779.20 61664.60 8.29 66779.20 61664.60 8.29
Other Income 214.90 151.00 42.32 712.90 1112.90 -35.94 712.90 1112.90 -35.94
PBIDT 3800.80 3074.40 23.63 15963.20 13226.70 20.69 15963.20 13226.70 20.69
Interest 162.00 240.60 -32.67 630.40 1206.70 -47.76 630.40 1206.70 -47.76
PBDT 823.40 1890.60 -56.45 12517.40 10686.40 17.13 12517.40 10686.40 17.13
Depreciation 651.90 617.60 5.55 2519.70 2464.80 2.23 2519.70 2464.80 2.23
PBT 171.50 1273.00 -86.53 9997.70 8221.60 21.60 9997.70 8221.60 21.60
TAX 822.00 625.40 31.44 3490.10 2917.50 19.63 3490.10 2917.50 19.63
Deferred Tax 63.00 6.30 900.00 81.10 37.40 116.84 81.10 37.40 116.84
PAT -650.50 647.60 -200.45 6507.60 5304.10 22.69 6507.60 5304.10 22.69
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 23.20 20.35 13.98 23.90 21.45 11.45 23.90 21.45 11.45

Ipca Laboratories Share Price

1557.90 -5.80 (-0.37%)
07-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1831.30
Dr. Reddys Lab 1307.00
Cipla 1361.00
Zydus Lifesciences 940.10
Lupin 2460.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×